Groundbreaking Phase 1 Results for CASI Pharmaceuticals’ BI-1206 Treatment for Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma in China.
Biopharmaceutical Company Announces Positive Interim Results For Non-Hodgkin's Lymphoma
Biopharmaceutical Company Announces Positive…
Biopharmaceutical Company Announces Positive Interim Results For Non-Hodgkin's Lymphoma
Groundbreaking Phase 1 Results for CASI Pharmaceuticals’ BI-1206 Treatment for Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma in China.